BNP Paribas Arbitrage SA raised its stake in Medidata Solutions, Inc. (NASDAQ:MDSO) by 153.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,304 shares of the company’s stock after buying an additional 17,133 shares during the period. BNP Paribas Arbitrage SA owned about 0.05% of Medidata Solutions worth $2,213,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Airain ltd acquired a new position in shares of Medidata Solutions during the first quarter valued at approximately $439,000. Parametric Portfolio Associates LLC increased its position in shares of Medidata Solutions by 1.8% in the first quarter. Parametric Portfolio Associates LLC now owns 91,576 shares of the company’s stock valued at $5,283,000 after buying an additional 1,618 shares in the last quarter. Oregon Public Employees Retirement Fund acquired a new position in shares of Medidata Solutions during the second quarter valued at approximately $925,000. LS Investment Advisors LLC increased its position in shares of Medidata Solutions by 49.5% in the second quarter. LS Investment Advisors LLC now owns 4,947 shares of the company’s stock valued at $387,000 after buying an additional 1,637 shares in the last quarter. Finally, Parametrica Management Ltd acquired a new position in shares of Medidata Solutions during the second quarter valued at approximately $216,000. 97.53% of the stock is currently owned by institutional investors.

Shares of Medidata Solutions, Inc. (MDSO) opened at 74.96 on Friday. Medidata Solutions, Inc. has a 52 week low of $46.10 and a 52 week high of $85.92. The company has a 50-day moving average price of $75.72 and a 200 day moving average price of $68.55. The firm has a market cap of $4.24 billion, a price-to-earnings ratio of 121.10 and a beta of 1.79.

Medidata Solutions (NASDAQ:MDSO) last announced its earnings results on Tuesday, July 18th. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.03. The company had revenue of $137.41 million for the quarter, compared to analyst estimates of $134.28 million. Medidata Solutions had a return on equity of 11.14% and a net margin of 7.07%. The firm’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.24 earnings per share. Analysts expect that Medidata Solutions, Inc. will post $1.28 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Medidata Solutions, Inc. (MDSO) Stake Boosted by BNP Paribas Arbitrage SA” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/01/medidata-solutions-inc-mdso-stake-boosted-by-bnp-paribas-arbitrage-sa.html.

MDSO has been the topic of several recent analyst reports. Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Friday, July 21st. SunTrust Banks, Inc. lifted their price target on Medidata Solutions from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, June 27th. Morgan Stanley lifted their price target on Medidata Solutions from $74.00 to $86.00 and gave the stock an “overweight” rating in a research report on Thursday, July 20th. Citigroup Inc. restated a “buy” rating and set a $95.00 price objective (up from $94.00) on shares of Medidata Solutions in a research report on Monday, July 24th. Finally, J P Morgan Chase & Co boosted their price objective on Medidata Solutions to $87.00 and gave the company an “overweight” rating in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $80.83.

In other news, Director Robert Taylor sold 5,639 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $73.46, for a total transaction of $414,240.94. Following the transaction, the director now owns 54,372 shares in the company, valued at $3,994,167.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Michael L. Capone sold 5,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $74.53, for a total value of $372,650.00. The disclosure for this sale can be found here. 5.80% of the stock is currently owned by company insiders.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Stock Ratings for Medidata Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions Inc. and related stocks with our FREE daily email newsletter.